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Cardiac allograft vasculopathy (CAV) remains one of the most
mportant causes of late graft failure and death in heart transplant
ecipients [1]. CAV is a progressive coronary artery disease charac-
erized by diffuse and progressive thickening of the intima along
he entire length of the epicardial and intramyocardial arteries [2].
AV is largely caused by various immunologic factors, which act on
he wall of the graft coronary vessels damaging the endothelium
nd triggering the release of proliferative substances and the adhe-
ion of platelets and mononuclear cells [3]. According to the ofﬁcial
eport of the International Society for Heart and Lung Transplanta-
ion, with a registry of more than 65 000 heart transplants, a CAV
revalence of 7% was found at the ﬁrst year, 32% at 5 years, and 53%
t 10 years after transplantation [4]. The symptoms do not usually
ppear until advanced stages of CAV because of cardiac denerva-
ion produced during transplantation. Therefore, silent myocardial
nfarction, heart failure, and sudden death are the most common
orms of presentation [5]. Because of possible lack of symptoms,
arious methods of evaluating CAV have been employed. Intravas-
ular ultrasound (IVUS) has been used as the gold standard for
he detection and monitoring of CAV [5]. Since sensitivity of coro-
ary angiography is low, an apparently normal angiography can
nderestimate the presence of advanced CAV.
Recently, the use of proliferation signal inhibitors such as
verolimus has been shown to signiﬁcantly prevent CAV com-
ared to other immunosuppressive regimens [6,7]. A combination
f a calcineurin inhibitor, mycophenolate mofetil, and a glucocorti-
oid is commonly used for maintenance immunosuppression after
eart transplantation. Chou et al. [8] showed that an everolimus
egimen can signiﬁcantly suppress lumen diameter and circum-
erence assessed by IVUS compared to a mycophenolate mofetil
egimen. It was suggested that everolimus can improve estab-
ished CAV as well as prevent the progression of CAV [7,9].
n the present study, Nakatani et al. clearly showed a case
ith remarkable plaque regression associated with everolimus
dministration [10]. Although serial angiographies did not detect
bvious stenosis during the follow-up period, an increased focal
ccentric plaque was observed by IVUS at 1 and 2 years after
DOI of original article: http://dx.doi.org/10.1016/j.jccase.2013.02.003.
878-5409/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2013.03.008transplantation. They added everolimus to the patient’s existing
regimen and withdrew mycophenolate mofetil. It is established
that an increase of ≥0.5 mm in intimal thickness is signiﬁcantly
associated with higher rates of cardiac events and a poorer
prognosis [11]. In a randomized, multicenter trial, conversion to
everolimus combined with reduced calcineurin inhibitor did not
inﬂuence CAV progression among maintenance heart transplanta-
tion recipients [12]. However, patients with everolimus combined
with azathioprine demonstrated attenuated CAV progression and
a decline in inﬂammatory markers, whereas the opposite pat-
tern was seen with everolimus combined with mycophenolate
mofetil. On the other hand, everolimus combined with mycopheno-
late improves renal function, whereas everolimus combined with
reduced cyclosporine deteriorates renal function [13]. The opti-
mal  combination regimen has not yet been established. According
to virtual histology assessment of CAV in a multicenter Scandina-
vian study [14], conversion to everolimus combined with reduced
calcineurin inhibitor is associated with a signiﬁcant increase in cal-
ciﬁed and necrotic intimal components and is more prominent in
patients with a longer time after heart transplantation. Everolimus
has not yet been approved by the US Food and Drug Administra-
tion to prevent organ rejection in heart transplantation recipients.
Everolimus may  be an alternative immunosuppressive drug for
maintenance therapy with good results. Further investigations are
needed to investigate long-term efﬁcacy and safety [15].
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